| Literature DB >> 22747760 |
Qingdi Quentin Li1, Jeff Skinner, John E Bennett.
Abstract
BACKGROUND: The selection of stable and suitable reference genes for real-time quantitative PCR (RT-qPCR) is a crucial prerequisite for reliable gene expression analysis under different experimental conditions. The present study aimed to identify reference genes as internal controls for gene expression studies by RT-qPCR in azole-stimulated Candida glabrata.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22747760 PMCID: PMC3482582 DOI: 10.1186/1471-2199-13-22
Source DB: PubMed Journal: BMC Mol Biol ISSN: 1471-2199 Impact factor: 2.946
strains used in this study
| | Wild-type (ATCC90030)* | 64 | [ | |
| NCCLS84 | Δ | 256 | [ | |
| Cg84u | 1 | [ | ||
| | Clinical susceptible isolate | 32 | [ | |
| Clinical resistant isolate | >256 | [ |
*American Type Culture Collection, Manassas, VA, USA.
Stability of RNA transcription of reference genes in fluconazole-treated as determined by the 2 method
| 0.34 | 0.39 | 0.46 | 1.34 | 1.56 | 1.60 | 2.17 | 2.41 | 2.60 | 2.89 | 3.13 | 3.67 | 4.12 | 4.17 | 4.45 | 5.03 | |
| 0.12 | 0.07 | 0 | -0.87 | -1.10 | -1.13 | -1.71 | -1.95 | -2.13 | -2.43 | -2.66 | -3.21 | -3.65 | -3.71 | -3.98 | -4.57 | |
| 0.92# | 0.95# | 1.00 | 1.83* | 2.14* | 2.19* | 3.28* | 3.86* | 4.39* | 5.38* | 6.32* | 9.23* | 12.58* | 13.06* | 15.82* | 23.75* | |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 |
CT Change = CT(ut) − CT(t); ut, untreated; t, fluconazole-treated.
ΔCT = CTreference − CTRDN5.8; ΔCT of each reference gene was calculated using RDN5.8 as the internal control.
ΔΔCT(t) = ΔCT(t) − ΔCT(ut).
2-ΔΔCT(t) for fluconazole-treated cells indicates fold change in RNA transcription of a reference gene normalized to RDN5.8, as compared with untreated cells.
The stability ranking is based on the values of CT Change, ΔΔCT(t), and 2-ΔΔCT(t) of the reference genes in fluconazole-treated C. glabrata cells.
#P > 0.05 and *P <; 0.05 for the azole-treated group vs. the untreated group after normalizing to RDN5.8.
Assessment of reference gene expression stability in fluconazole-treated by using hkgFinder
| 0.19 | 0.22 | 0.26 | 0.73 | 0.87 | 0.88 | 1.19 | 1.33 | 1.42 | 1.58 | 1.71 | 2.01 | 2.26 | 2.28 | 2.44 | 2.76 | |
| -0.35 | -0.39 | -0.46 | -1.33 | -1.56 | -1.60 | -2.18 | -2.41 | -2.60 | -2.89 | -3.12 | -3.67 | -4.12 | -4.17 | -4.45 | -5.03 | |
| 1.2 | 1.3 | 1.4 | 2.5 | 2.9 | 3.0 | 4.5 | 5.3 | 6.0 | 7.4 | 8.7 | 12.7 | 17.4 | 18.0 | 21.8 | 32.7 | |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 |
The fold change shown in the table represents the difference in reference gene expression between azole-treated and untreated C. glabrata without normalization to an internal control gene.
The stability ranking is based on the values of standard deviation (SD), log fold change, and fold change of reference genes in fluconazole-treated C. glabrata cells. The best reference genes will have the smallest SD and smallest fold-change values.
Figure 1Determination of the average expression stability () of the reference genes using the geNorm program. The reference genes were serially excluded from the analysis, with M representing the mean pairwise variation between an individual reference gene and all other tested reference genes. The reference gene indicated at each point on the x-axis is the one that is to be excluded from the following step. The most stable reference genes are those that are still included, i.e., those that exhibit the lowest M values. Shown is the stability ranking of the reference genes in all samples. Genes are ranked from left to right in order of increasing expression stability (decreasing M value)
Comparison of reference gene expression stability* as determined by four different software packages
| 0.042 | 0.983 | 0.425 | 1.2 | ||||
| 0.050 | 0.978 | 0.459 | 1.3 | ||||
| 0.055 | 0.974 | 0.460 | 1.4 | ||||
| 0.357 | 0.915 | 0.534 | 2.5 | ||||
| 0.478 | 0.908 | 0.922 | 2.9 | ||||
| 0.500 | 0.901 | 0.935 | 3.0 | ||||
| 0.849 | 0.864 | 0.961 | 8.7 | ||||
| 1.103 | 0.857 | 0.993 | 18.0 | ||||
| 1.167 | 0.856 | 1.200 | 21.8 | ||||
| 1.258 | 0.836 | 1.480 | 32.7 | ||||
*Genes are listed from most to least stable for all four methods.
, geNorm stability parameter. Mean, stability value.
, all 10 candidate reference genes were correlated and were combined to calculate the BestKeeper index, which was then used to determine the correlation between each reference gene and the index.
Figure 2Determination of the optimal number of reference genes as internal references for normalization using geNorm analysis. The geNorm program calculates a normalization factor from at least two reference genes and the mean pairwise variation (V) between every combination of sequential normalization factors in order to determine the minimum number of reference genes required for accurate normalization in the samples. For example, V5/6 represents the comparison of the normalization factors from five and six reference genes, respectively. On the left-most side is the pairwise variation when the number of reference genes is increased from two to three (V2/3). Stepwise inclusion of less stable genes generates the subsequent data points. A decrease in the V value indicates a positive effect and means that the added gene should preferably be included for calculation of a reliable normalization factor. The cutoff value for V, below which the inclusion of an additional reference gene does not result in a significant improvement of normalization, was set at 0.15. It was apparent from the analysis of all studied samples that the combination of the two most stable reference genes is the best option and the combination of the five most stable reference genes is the second-best option for accurate normalization
Validation of reference gene suitability as an internal control based on the correlation of amplification efficiency between reference and target genes in fluconazole-treated cells
| 0.056 | 0.072 | 0.061 | 0.019 | 0.033 | 0.046 | 0.034 | 0.095 | 0.054 | 0.043 | |
| 0.018 | 0.049 | 0.014 | 0.059 | 0.094 | 0.057 | 0.032 | 0.024 | 0.046 | 0.028 | |
| 0.084 | 0.065 | 0.014 | 0.021 | 0.014 | 0.086 | 0.060 | 0.060 | 0.029 | 0.061 | |
| 0.187 | 0.315 | 0.304 | 0.262 | 0.210 | 0.836 | 0.689 | 0.689 | 0.778 | 0.688 | |
| 0.015 | 0.051 | 0.012 | 0.062 | 0.096 | 0.077 | 0.052 | 0.044 | 0.066 | 0.048 | |
| 0.069 | 0.051 | 0.028 | 0.035 | 0 | 0.079 | 0.068 | 0.068 | 0.022 | 0.069 |
Each value is the slope m of the line (Y = mx + b) of the validation experiment and reflects the correlation of reference gene and target gene amplification efficiencies.
An absolute slope value <;0.1 is generally used as a criterion for passing a validation experiment, as it indicates that the amplification efficiency is approximately equal between the reference and target genes.
The slope m = 0 indicates that the efficiencies of the two PCR reactions are equal.
Comparison of fluconazole-induced target gene expression among five different strains using or as the reference for normalization
| 2.12* | 0.19* | 2.22* | 0.20* | 2.85* | 0.26* | |
| 3.90* | 0.42* | 3.26* | 0.50* | 10.04* | 0.68* | |
| 0.64# | 0.06* | 1.08# | 0.10* | 2.42* | 0.22* | |
| 2.59* | 0.23* | 3.31* | 0.30* | 3.84* | 0.35* | |
| 2.14* | 0.19* | 3.68* | 0.33* | 5.34* | 0.48* | |
¶Values indicate the fold change in RNA transcription for each target gene in fluconazole-treated C. glabrata, as compared with untreated cells.
ΔCT = CTtarget − CTreference; ΔCT of each target gene was calculated by using RDN5.8 or ACT1 as the reference.
ΔΔCT(t) = ΔCT(t) − ΔCT(ut); ut, untreated; t, fluconazole-treated. Fold change = 2-ΔΔCT(t).
Fold changes of the target genes were also computed with the hkgFinder tool by using RDN5.8 or ACT1 as the reference.
#P > 0.05 and *P <; 0.05 for the azole-treated group vs. the untreated group after normalization to RDN5.8 or ACT1.
Comparison of the relative mRNA expression levels* of four target genes in fluconazole-treated when normalized to different reference genes
| 0.26 | 0.27 | 0.70 | 1.21 | |
| 4.07 | 4.27 | 11.08 | 19.07 | |
| 1.90 | 1.99 | 5.17 | 8.90 | |
| 2.23 | 2.33 | 6.06 | 10.43 | |
| 2.79 | 2.92 | 7.59 | 13.06 | |
| 3.01 | 3.15 | 8.19 | 14.09 | |
| 2.58 | 2.71 | 7.03 | 12.10 |
*Values indicate the fold change in RNA transcription for each target gene in fluconazole-treated C. glabrata after normalization to one or more reference genes, as compared with untreated cells.
ΔCT = CTtarget − CTreference.
ΔΔCT(t) = ΔCT(t) − ΔCT(ut); ut, untreated; t, fluconazole-treated. Fold change = 2-ΔΔCT(t).
Fold changes of the target genes were also computed with the hkgFinder tool by using one or more reference genes as the internal control for normalization
P <; 0.05 vs. untreated cells, for all values shown in the table after normalizing to one or more reference genes as indicated.